An Exploratory Study by Fast CAR T Cells

Inclusion Criteria:

• Patients diagnosed with advanced solid tumors through histopathological diagnosis havea positive rate of ≥ 50% for mesothelin expression membrane and ≥ 50% for MUC1expression in tumor tissue samples. PD-L1 expression is positive, and the samplesource is within 2 years；
• Late stage malignant solid tumor patients who have failed standard treatment or areintolerant to such treatment and do not have a standard effective treatment plan ；
• Greater than or equal to 18 years of age and less than or equal to 70 years of age onday of signing informed consent；
• Life expectancy >3 months；
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；
• Satisfactory organ and bone marrow function as defined by the following：

1. absolute neutrophil count must be greater than ≥ 1.5×10^9/L, lymphocyte countmust be greater than ≥ 0.5×10^9/L, platelets must be greater than ≥ 90×10^9/L,hemoglobin must be greater than ≥ 90g/L without transfusion within 7 days ordependency on EPO;
2. Total bilirubin must be less than or equal to two times (≤2.0x) the institutionalnormal upper limit; transaminases, serum alanine aminotransferase (ALT) oraspartate aminotransferase (AST), must be less than or equal to 2.5 times (≤2.5x)the institutional normal upper limit (≤5x if there is hepatic metastasis);
3. International normalized ratio (INR) or the PT is not greater than one and onehalf times (≤ 1.5) the upper limit of normal;
4. Lung function: ≤ CTCAE grade 1 dyspnea and SaO2≥ 91%；
5. Cardiac function: cardiac ejection fraction (LVEF) must be greater than fiftypercent (≥50%) by echocardiogram or MUGA one month before enrollment.

• Subjects must have measureable disease as defined by RECIST 1.1 criteria;
• Subjects sufficiently understand the trial and willingly sign the informed consent；
• Male and Female subjects agree to use approved contraceptive methods (e.g. birthcontrol pills, barrier device, intrauterine device, abstinence) during the study andfor at least 12 months following the last dose of the study cell infusion and until noCAR-T cells can be detected after two consecutive PCR tests.

Exclusion Criteria:

• Subjects who have undergone other anti-tumor treatments (including radiation therapy,chemotherapy, small molecule, biological or immunotherapy, and other study drugs)other than lymphocytes depletion allowed by the protocol within one month prior toCAR-T infusion;
• Prior therapy with any gene therapy (including CAR-T cell therapy) or any T celltherapy home and abroad;
• Pregnant or breastfeeding women;
• Positive serological reactions for HIV and syphilis; Hepatitis B surface antigenpositive, hepatitis B core antibody positive, and hepatitis B virus DNA copy numberhigher than the detection limit and/or greater than or equal to 1000 copies/mL; OrHepatitis C virus infected individuals;
• Any uncontrollable active infection, coagulation disorders, or any other majorillness;
• Patients with autoimmune diseases, organ transplantation and other immune relateddiseases under treatment, or long-term use of immunosuppressive drugs such asglucocorticoids: a. Glucocorticoids: users cannot stop using CAR-T cells 72 hoursbefore infusion; b. Immunosuppressants other than glucocorticoids cannot be stopped ≥ 4 weeks before enrollment;
• History of severe cardiac or pulmonary disease, including hypertension that cannot becontrolled by medication, and any of the conditions occurred within the past 6 months:congestive heart failure (New York Heart Association functional classification ≥3),cardiac angioplasty and stents, myocardial infarction, unstable angina, or otherclinically significant heart disease;
• Detectable clinically relevant central nervous system (CNS) metastases and/orpathology such as epilepsy/seizure, brain Ischemia/ hemorrhage, dementia, cerebellardisease, or autoimmune disease affecting central nervous system.
• Patients at high risk of causing bleeding or perforation;
• Patients who had undergone major surgical procedures or significant trauma within 4weeks before apheresis, or who were expected to require major surgery during the studyperiod;
• Patient has a known history of a hematologic malignancy, or of another malignantprimary solid tumor concurrently, with the exception of :Patients with in situcervical cancer or breast cancer with no evidence of disease for ≥ 3 years aftercurative treatments;Patients who underwent successful definitive resection of in situcancer with no evidence of disease for ≥5 years;
• Other circumstances that were deemed by the investigator to be inappropriate for trialparticipation.